A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Stella acts as an intermediary. Researcher contact info is never exposed.